Supreme Court Ruling Upholds Patent Settlements with Consideration as a Valid Means to Generic Access for Patients

Published Online: Monday, June 17, 2013
Follow Pharmacy_Times:
PRESS RELEASE
 
June 17, 2013 (WASHINGTON, DC) The Generic Pharmaceutical Association (GPhA) welcomes today’s decision from the Supreme Court in the FTC vs. Actavis case, upholding several previous rulings from district courts that recognize the complex nature of these cases, and rejecting the Federal Trade Commission’s assessment that all settlements with consideration are presumptively illegal.
 
“Today, generic drugs are more available to patients than they have ever been, and we want to preserve every legal avenue to continue that success,” said Ralph G. Neas, President and CEO of the GPhA. “The fact is that patent settlements have resulted in hundreds of generic options coming to market -- on average nearly five years in advance of the brand patent’s end date. This means billions of dollars in savings for consumers and the health system.”
 
“We are pleased that the Court clearly recognized that settlements require a case-by-case assessment. In establishing the ‘rule of reason,’ and leaving the decision to lower courts, the ruling continues to provide a lawful pathway for companies to resolve disputes through settlements,” continued Neas. “This preserves all options for generic manufacturers to bring lower-cost generic medicines to patients as soon as possible.”
 
At the same time, the Court’s ruling will require generic companies to take on a greater administrative burden to pursue a patent challenge, potentially lowering the number of challenges. As a result, consumers may have access to fewer generic options.
 
Generic companies assert patent challenges under the 1984 Hatch-Waxman law, which is intended to balance incentives for innovative new drugs with speeding lower cost generic medicines to the market. With generics making up more than 84 percent of the market, Hatch-Waxman has been a proven success in providing choices to patients and cost-savings to the U.S. health care system for nearly 30 years.  In the last 10 years alone, generic drugs have saved consumers and the health system more than a trillion dollars.
 
References:
Pharmaceutical Patent Settlements: Myths and Facts
Frequently Asked Questions about Pharmaceutical Patent Settlements
RBC Capital Markets: Analyzing Litigation Success Rates
GPhA amicus brief in FTC v. Actavis
White paper: S. 214’s Inappropriate Interference With the Fundamental Right to Settle Litigation
Related Articles
The Generic Pharmaceutical Association welcomes the FDA’s proposed rule to amend its prescription drug and biological product labeling regulations to require electronic distribution of the prescribing information intended for healthcare professionals.
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues
$auto_registration$